EPP drug levels measured in teens and adults
NCT ID NCT06388642
First seen Dec 02, 2025 · Last updated May 13, 2026 · Updated 12 times
Summary
This study looked at how the drug afamelanotide is processed in the body of 28 people with erythropoietic protoporphyria (EPP), a rare condition causing severe sun sensitivity. Participants were aged 12 to 70 and had a healthy weight. The main goal was to measure the drug's concentration in the blood over time. This was a completed early-phase study (Phase 1/2) focused on gathering information, not on treating symptoms.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ERYTHROPOIETIC PROTOPORPHYRIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CLINUVEL Site
Leuven, Belgium
-
CLINUVEL Site
Rotterdam, Netherlands
Conditions
Explore the condition pages connected to this study.